Impact of preoperative blood glucose levels on prognosis and postoperative complications in patients with pancreatic cancer

被引:0
作者
Wang, Shubin [1 ]
Pan, Teng [2 ]
Wang, Shuya [3 ]
Zhang, Xiaokun [1 ]
Peng, Li [4 ]
Yang, Wuhan [4 ]
机构
[1] Hebei Med Univ, Hosp 4, Dept Gen Med, Shijiazhuang 050000, Hebei, Peoples R China
[2] Shijiazhuang First Hosp, Dept Oncol, Shijiazhuang 050011, Hebei, Peoples R China
[3] Dalian Med Univ, Dept Gen Med, Dalian 116000, Liaoning, Peoples R China
[4] Hebei Med Univ, Hosp 4, Dept Hepatobiliary Surg, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China
关键词
hyperglycemia; diabetes mellitus; pancreatic cancer; carbohydrate antigen 19-9; overall survival; DIABETES-MELLITUS; OUTCOMES; RISK;
D O I
10.3892/ol.2025.14880
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between diabetes and pancreatic cancer is well documented; however, the effect of preoperative blood glucose levels on prognosis and postoperative complications is currently unclear. The present study aimed to investigate the effect of preoperative blood glucose levels on overall survival (OS) and postoperative complications in patients with pancreatic cancer. This retrospective study included 225 patients with pancreatic cancer treated at The Fourth Hospital of Hebei Medical University from January 2015 to December 2020. Patients were grouped based on preoperative blood glucose levels (normal, <= 6.11 mmol/l; high, >6.11 mmol/l). Data on demographics, clinical history, tumor characteristics, treatment and laboratory results were collected. High preoperative blood glucose levels were associated with reduced OS time [hazard ratio (HR), 1.68; 95% confidence interval (CI), 1.15-2.45; P=0.007] and increased postoperative complications (29.2 vs. 9.8%; chi(2)=13.658; P<0.001). Median OS time was significantly shorter in the high glucose group (14.2 vs. 20.5 months; HR, 1.96; 95% CI, 1.38-2.77; P<0.001). Elevated CA19-9 levels were also a predictor of poor OS (HR, 1.70; 95% CI, 1.06-2.74; P=0.029). High preoperative blood glucose and elevated CA19-9 levels were independent predictors of poor prognosis in patients with pancreatic cancer. This finding suggests that preoperative blood glucose levels have a greater impact on prognosis compared with a history of diabetes. Elevated preoperative blood glucose levels have poorer OS and a higher incidence of postoperative complications compared to those with lower preoperative glucose levels, underscoring the importance of preoperative glucose management. Effective preoperative blood glucose control may improve outcomes in patients with pancreatic cancer.
引用
收藏
页数:11
相关论文
共 39 条
  • [1] Diabetes mellitus-Progress and opportunities in the evolving epidemic
    Abel, E. Dale
    Gloyn, Anna L.
    Evans-Molina, Carmella
    Joseph, Joshua J.
    Misra, Shivani
    Pajvani, Utpal B.
    Simcox, Judith
    Susztak, Katalin
    Drucker, Daniel J.
    [J]. CELL, 2024, 187 (15) : 3789 - 3820
  • [2] Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer
    Andersen, Dana K.
    Korc, Murray
    Petersen, Gloria M.
    Eibl, Guido
    Li, Donghui
    Rickels, Michael R.
    Chari, Suresh T.
    Abbruzzese, James L.
    [J]. DIABETES, 2017, 66 (05) : 1103 - 1110
  • [3] Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review
    Ballehaninna U.K.
    Chamberlain R.S.
    [J]. Indian Journal of Surgical Oncology, 2011, 2 (2) : 88 - 100
  • [4] Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study
    Balzano, Gianpaolo
    Dugnani, Erica
    Gandolfi, Alessandra
    Scavini, Marina
    Pasquale, Valentina
    Aleotti, Francesca
    Liberati, Daniela
    Di Terlizzi, Gaetano
    Petrella, Giovanna
    Reni, Michele
    Doglioni, Claudio
    Bosi, Emanuele
    Falconi, Massimo
    Piemonti, Lorenzo
    [J]. PLOS ONE, 2016, 11 (11):
  • [5] Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma
    Bhandare, Manish S.
    Gupta, Vikas
    Chaudhari, Vikram
    Nandy, Kunal
    Ostwal, Vikas
    Ramaswamy, Anant
    Nashikkar, Chaitali
    Engineer, Reena
    Krishnatry, Rahul
    Shrikhande, Shailesh V.
    [J]. HPB, 2024, 26 (10) : 1237 - 1247
  • [6] A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes
    Boursi, Ben
    Finkelman, Brian
    Giantonio, Bruce J.
    Haynes, Kevin
    Rustgi, Anil K.
    Rhim, Andrew D.
    Mamtani, Ronac
    Yang, Yu-Xiao
    [J]. GASTROENTEROLOGY, 2017, 152 (04) : 840 - +
  • [7] The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link
    Bowers, Laura W.
    Rossi, Emily L.
    O'Flanagan, Ciara H.
    deGraffenried, Linda A.
    Hursting, Stephen D.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2015, 6
  • [8] Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus
    Bures, Jan
    Kohoutova, Darina
    Skrha, Jan
    Bunganic, Bohus
    Ngo, Ondrej
    Suchanek, Stepan
    Skrha, Pavel
    Zavoral, Miroslav
    [J]. CANCERS, 2023, 15 (14)
  • [9] Biomarker method validation in anticancer drug development
    Cummings, J.
    Ward, T. H.
    Greystoke, A.
    Ranson, M.
    Dive, C.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (04) : 646 - 656
  • [10] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    Currie, C. J.
    Poole, C. D.
    Gale, E. A. M.
    [J]. DIABETOLOGIA, 2009, 52 (09) : 1766 - 1777